Articles producció científica> Medicina i Cirurgia

Bifidobacterium longum subsp infantis CECT7210-supplemented formula reduces diarrhea in healthy infants: A randomized controlled trial

  • Identification data

    Identifier: imarina:6389449
    Authors:
    Escribano JFerré NGispert-Llaurado MLuque VRubio-Torrents CZaragoza-Jordana MPolanco ICodoñer FChenoll EMorera MMoreno-Muñoz JRivero MClosa-Monasterolo R
    Abstract:
    © 2018 International Pediatric Research Foundation, Inc. BackgroundIntestinal microbiota of breast-fed infants is plenty of beneficial bifidobacteria. We aimed to determine whether an infant formula supplemented with probiotic Bifidobacterium longum subsp. infantis CECT7210 (B. infantis IM1) is effective at reducing diarrhea incidence in healthy term infants.MethodsDouble blinded, randomized, multicenter, controlled clinical trial, where formula-fed infants (<3 months) received an infant formula supplemented (Probiotic) or not (Control) with 10 7 cfu/g of B. infantis IM1 over 12 weeks. Diarrheas, growth, digestive symptoms, stool bifidobacteria, and microbiota were assessed.ResultsIn all, 97 (Control) and 93 (Probiotic) infants were randomized, and 78 (Control) and 73 (Probiotic) completed the 12 week-follow-up. In the overall study period, a median of 0.29±1.07 and 0.05±0.28 diarrhea events/infant was observed in the Control and Probiotic groups, respectively (P=0.059). This trend to less diarrhea episodes in the Probiotic group reached statistical significance at 8 weeks (0.12±0.47 vs. 0.0±0.0 events/infant, P=0.047). Constipation incidence was higher (odds ratio (OR) 2.67 (1.09-6.50)) and stool frequency lower (2.0±1.0 vs. 2.6±1.3 stools/day, P=0.038) in the Control group after 4 weeks. No differences were found at other time points nor in other digestive symptoms, growth, or formula intake.ConclusionA B. infantis IM1-supplemented infant formula may reduce diarrhea episodes, being safe, well tolerated, and associated with lower constipation prevalence.
  • Others:

    Author, as appears in the article.: Escribano J; Ferré N; Gispert-Llaurado M; Luque V; Rubio-Torrents C; Zaragoza-Jordana M; Polanco I; Codoñer F; Chenoll E; Morera M; Moreno-Muñoz J; Rivero M; Closa-Monasterolo R
    Department: Medicina i Cirurgia
    URV's Author/s: Closa Monasterolo, Ricardo / Escribano Subías, Joaquín / Ferré Huguet, Núria / Ferre Pallas, Natalia / Gispert Llauradó, Mariona / Luque Moreno, Verònica / RUBIO TORRENTS, MARÍA DEL CARMEN / Zaragoza Jordana, Marta
    Abstract: © 2018 International Pediatric Research Foundation, Inc. BackgroundIntestinal microbiota of breast-fed infants is plenty of beneficial bifidobacteria. We aimed to determine whether an infant formula supplemented with probiotic Bifidobacterium longum subsp. infantis CECT7210 (B. infantis IM1) is effective at reducing diarrhea incidence in healthy term infants.MethodsDouble blinded, randomized, multicenter, controlled clinical trial, where formula-fed infants (<3 months) received an infant formula supplemented (Probiotic) or not (Control) with 10 7 cfu/g of B. infantis IM1 over 12 weeks. Diarrheas, growth, digestive symptoms, stool bifidobacteria, and microbiota were assessed.ResultsIn all, 97 (Control) and 93 (Probiotic) infants were randomized, and 78 (Control) and 73 (Probiotic) completed the 12 week-follow-up. In the overall study period, a median of 0.29±1.07 and 0.05±0.28 diarrhea events/infant was observed in the Control and Probiotic groups, respectively (P=0.059). This trend to less diarrhea episodes in the Probiotic group reached statistical significance at 8 weeks (0.12±0.47 vs. 0.0±0.0 events/infant, P=0.047). Constipation incidence was higher (odds ratio (OR) 2.67 (1.09-6.50)) and stool frequency lower (2.0±1.0 vs. 2.6±1.3 stools/day, P=0.038) in the Control group after 4 weeks. No differences were found at other time points nor in other digestive symptoms, growth, or formula intake.ConclusionA B. infantis IM1-supplemented infant formula may reduce diarrhea episodes, being safe, well tolerated, and associated with lower constipation prevalence.
    Thematic Areas: Serviço social Saúde coletiva Química Pediatrics, perinatology and child health Pediatrics Medicina ii Medicina i Interdisciplinar Ensino Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 00313998
    Author's mail: veronica.luque@urv.cat mariona.gispert@urv.cat mariona.gispert@urv.cat marta.zaragoza@urv.cat marta.zaragoza@urv.cat nuria.ferre@urv.cat ricardo.closa@urv.cat natalia.ferre@urv.cat joaquin.escribano@urv.cat
    Author identifier: 0000-0003-2615-8175 0000-0002-9963-4163 0000-0002-2838-1525 0000-0002-5041-459X
    Record's date: 2024-10-12
    Papper version: info:eu-repo/semantics/acceptedVersion
    Link to the original source: https://www.nature.com/articles/pr201834
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Pediatric Research. 83 (6): 1120-1128
    APA: Escribano J; Ferré N; Gispert-Llaurado M; Luque V; Rubio-Torrents C; Zaragoza-Jordana M; Polanco I; Codoñer F; Chenoll E; Morera M; Moreno-Muñoz J; Ri (2018). Bifidobacterium longum subsp infantis CECT7210-supplemented formula reduces diarrhea in healthy infants: A randomized controlled trial. Pediatric Research, 83(6), 1120-1128. DOI: 10.1038/pr.2018.34
    Article's DOI: 10.1038/pr.2018.34
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    Publication Type: Journal Publications
  • Keywords:

    Pediatrics,Pediatrics, Perinatology and Child Health
    Serviço social
    Saúde coletiva
    Química
    Pediatrics, perinatology and child health
    Pediatrics
    Medicina ii
    Medicina i
    Interdisciplinar
    Ensino
    Educação física
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar